Performance of Elecsys^® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection.

ABSTRACT:

Background/objectives

The Elecsys^® HCV Duo immunoassay (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) detects both antibodies to hepatitis C virus (anti-HCV) and HCV core antigen (HCV-Ag) and has shown excellent diagnostic performance in blood donor samples. We aim to validate its use for diagnosing chronic HCV infection and assessing sustained virological response (SVR) post-direct-acting antivirals (DAAs) in patients with or without HIV infection.

Methods

Blood samples from 100 healthy controls, as well as 64 HCV mono-infection and 136 HCV-HIV coinfections, were collected before and 12-24 weeks after DAAs. The assay performance for determining active infection at baseline and SVR was compared with HCV RNA.

Results

Overall, 156 (78.0%) of HC

SUBMITTER: Ananchuensook P 

PROVIDER: S-EPMC11475452 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature